Legal status · United Kingdom
Is Mitoglitazone legal in the United Kingdom?
Written by Aaron CuhaReviewed Sep 2026
Direct answer
No. Mitoglitazone is not approved for any medical use in the United Kingdom; its classification is "Investigational, not licensed". Lawful access is limited to registered clinical trials. "Research use only" labeling on vials sold online does not make human use lawful. On the evidence, 4 human studies are cited on its profile.
Mitoglitazone in the United Kingdom at a glance
| Classification | Investigational, not licensed |
|---|---|
| MHRA approval status | Not approved by MHRA; investigational |
| Human studies cited | 4 of 8 citations on the profile |
| Reviewed | Sep 2026 |
Classification and note come from the Mitoglitazone profile, checked against Medicines and Healthcare products Regulatory Agency (MHRA) listings at the reviewed date.
What this means
- 01
Mitoglitazone is being studied in registered clinical trials but has not received MHRA marketing approval in the United Kingdom.
- 02
Lawful human access is limited to trial participation or a formal early-access scheme where one exists; there is no pharmacy product to prescribe.
- 03
Vials sold online "for research use only" are not trial material, and that label does not make human use lawful.
What Mitoglitazone is
Extended male mouse median lifespan by 8.7 percent when started at 7 months, then failed a retest started at 18 months where it shortened female lifespan. In people it has completed a 356-patient phase 2b in type 2 diabetes and a 29-patient phase 2 in Alzheimer disease, both sponsor-run, neither followed by a phase 3.
Mitoglitazone is a thiazolidinedione designed to keep the insulin-sensitising effect of pioglitazone while largely avoiding the PPAR-gamma activation blamed for that class's fluid retention and weight gain. Its developer, Metabolic Solutions Development Company, traced the PPAR-gamma-independent action to a mitochondrial target it called mTOT, later identified as the mitochondrial pyruvate carrier (MPC1 and MPC2).
Mechanism: Mitoglitazone binds the mitochondrial pyruvate carrier complex (MPC1 and MPC2), identified by photo-crosslinking proteomics as the mitochondrial target of thiazolidinediones, and has minimal affinity for PPAR-gamma. Restricting pyruvate entry into mitochondria shifts fuel use and, in the developer's model, produces insulin sensitisation without the PPAR-gamma-driven fluid retention and adipose expansion.
Regulatory history: Investigational, not approved. Completed phase 2 in type 2 diabetes (2011) and Alzheimer disease (2013) with results posted; no phase 3 registered. The lifespan extension is in male mice started at 7 months; the retest started at 18 months found no male benefit and shorter female lifespan.
How MHRA treats this kind of product
Licenses medicines for the UK market. A compound without a marketing authorisation is an unlicensed medicine, which can only lawfully be supplied for human use through a prescriber under the specials scheme, not sold as a research product.
The classification above is the The Longevity Archive reading of Medicines and Healthcare products Regulatory Agency listings for Mitoglitazone at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.
Mitoglitazone in other countries
Frequently asked questions
Is Mitoglitazone legal in the United Kingdom?
No. Mitoglitazone is not approved for any medical use in the United Kingdom; its classification is "Investigational, not licensed". Lawful access is limited to registered clinical trials. "Research use only" labeling on vials sold online does not make human use lawful. On the evidence, 4 human studies are cited on its profile.
Can I buy Mitoglitazone in the United Kingdom?
No approved product exists to buy. In the United Kingdom Mitoglitazone is classified as "Investigational, not licensed", so there is no licensed pharmacy product. Vendors selling it "for research use only" are not selling it for human use, and that label does not change its legal status. This site does not list or recommend vendors.
Is Mitoglitazone MHRA approved?
No. In the United Kingdom Mitoglitazone is classified as "Investigational, not licensed", which is not a MHRA marketing approval. For comparison, the US FDA status is: Investigational, not approved. Completed phase 2 in type 2 diabetes (2011) and Alzheimer disease (2013) with results posted; no phase 3 registered. The lifespan extension is in male mice started at 7 months; the retest started at 18 months found no male benefit and shorter female lifespan.. On the evidence, 4 human studies are cited on its profile.
Related compounds in the United Kingdom
Full research profile
Mechanism, cited studies, FDA status and the full legal summary for Mitoglitazone live on its compound profile.
Mitoglitazone profileThis page is general information about the regulatory status of Mitoglitazone in the United Kingdom, current as of Sep 2026. It is not legal advice, and classifications change; check Medicines and Healthcare products Regulatory Agency directly or consult a lawyer for a specific situation. Educational use only. This database summarizes published research. It is not medical advice and contains no dosing protocols or recommendations for personal use. The Longevity Archive has no vendor relationships and does not recommend where to buy anything.